Binds Cancer Cell Or Component Or Product Thereof (e.g., Cell-surface Antigen, Etc.) Patents (Class 530/388.8)
  • Patent number: 10519251
    Abstract: The present invention provides multivalent and multispecific binding proteins that are capable of binding two or more antigens, or two or more epitopes. The present invention also provides methods of making and using such multivalent and multispecific binding proteins, including methods of using such binding proteins for prevention or treatment of various diseases, or for detecting specific antigens in vitro or in vivo.
    Type: Grant
    Filed: December 24, 2014
    Date of Patent: December 31, 2019
    Assignee: EpimAb Biotherapeutics, Inc.
    Inventor: Chengbin Wu
  • Patent number: 10385137
    Abstract: The invention concerns antibody formats comprising VH sequence of Camelidae, such as llamas; antibodies of various formats have anti-CEA or anti-CD16 VH sequences thereof; vectors expressing the antibody formats, and methods for producing the same.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: August 20, 2019
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Centre National de la Recherche Scientifique (CNRS), Universite d'Aix Marseille, Universite de Montpellier, Institut Regional du Cancer de Montpellier-Val D'Aurelle, Institut Paoli Calmettes
    Inventors: Daniel Baty, Ghislaine Behar, Martine Mansais, Andre Pelegrin, Jean-luc Teillaud, Isabelle Teulon
  • Patent number: 9598501
    Abstract: The present invention provides an antibody-immobilized carrier that can be used in antibody screening, a method of producing the antibody-immobilized carrier, and use of the antibody-immobilized carrier. Efficient antibody screening can be carried out particularly by an antibody-immobilized carrier including two or more antibody immobilized regions onto each of which a heavy-chain low-molecular-weight antibody and a light-chain low-molecular-weight antibody are separately immobilized, the two or more antibody immobilized regions each being included in an independent manner, the heavy-chain low-molecular-weight antibody including a heavy-chain variable region, the light-chain low-molecular-weight antibody including a light-chain variable region, the heavy-chain low-molecular-weight antibody and the light-chain low-molecular-weight antibody each being derived from an antibody recognizing a different antigen.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: March 21, 2017
    Assignees: NATIONAL UNIVERSITY CORPORATION KYOTO INSTITUTE OF TECHNOLOGY, DENKA SEIKEN CO., LTD
    Inventors: Yoichi Kumada, Michimasa Kishimoto, Kyoko Hamasaki, Aya Nakagawa
  • Patent number: 9320812
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of such modulators to treat hyperproliferative disorders are provided.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: April 26, 2016
    Assignee: Stemcentrx, Inc.
    Inventors: Johannes Hampl, Scott J. Dylla, Orit Foord, Robert A. Stull
  • Patent number: 9259440
    Abstract: The present invention relates to products and methods for preventing, ameliorating and/or treating infections and other diseases. In one aspect, the products of the present invention relates to compositions comprising germ free colostrum. In another aspect, the products of the present invention relates to compositions comprising synthetically multimerized immunoglobulins. In a third aspect, the products of the present invention relates to compositions comprising germ free colostrum enriched with synthetically multimerized immunoglobulins. The invention also relates to use of said compostions as a pharmaceutical e.g. for prophylactic or ameliorating treatment of infections and other diseases. In addition the invention comprises methods for production of said compositions.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: February 16, 2016
    Assignee: MULTIMERICS ApS
    Inventor: Kirsten Bisgaard-Frantzen
  • Patent number: 9261507
    Abstract: A method for diagnosing a cancer characterized by over expression of CEACAM1 using an anti-CEACAM1 antibody or antibody fragment that recognizes CEACAM1 and comprises the same CDR sequences in the same orientation as the CDRs of the antibody produced from a hybridoma cell which has been deposited under ATCC Accession Number PTA-9974.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: February 16, 2016
    Assignees: Tel Hashomer Medical Research Infrastructure and Services LTD., RAMOT AT TEL AVIV UNIVERSITY LTD.
    Inventors: Gal Markel, Rona Ortenberg, Jacob Schachter
  • Patent number: 9217033
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Glypican-3 with high affinity. Nucleic acid molecules encoding Glypican-3 antibodies, expression vectors, host cells and methods for expressing the Glypican-3 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the Glypican-3 antibodies are also provided. Methods for detecting Glypican-3, as well as methods for treating various Glypican-3-related conditions, including hepatocellular cancer, are disclosed.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: December 22, 2015
    Assignee: E. R. SQUIBB & SONS, L.L.C.
    Inventors: Jonathan Alexander Terrett, Li-Sheng Lu, Haichun Huang, Dapeng Yao, Chin Pan, Heidi N. LeBlanc, Tim W. Sproul, Mark Yamanaka
  • Patent number: 9206260
    Abstract: The present invention provides antigen binding molecules (ABMs) which bind membrane-bound CEA, including ABMs with improved therapeutic properties, and methods of using the same.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: December 8, 2015
    Assignee: Roche Glycart AG
    Inventors: Thomas U. Hofer, Ralf Hosse, Ekkehard Moessner, Pablo Umana
  • Patent number: 9062109
    Abstract: The present invention relates to a novel antibody against ephrin B2 and its use to detect the protein and as a medicament for inhibiting angiogenesis and lymphangiogenesis in the treatment of diseases in which these processes are implicated, for example, cancer.
    Type: Grant
    Filed: September 20, 2011
    Date of Patent: June 23, 2015
    Assignee: Fundacion Centro Nacional De Investigaciones Oncologicas (CNIO)
    Inventors: Jorge Luis Martinez Torrecuadrada, Maria Angeles Abengozar Infantes
  • Patent number: 9045546
    Abstract: The present invention provides molecules that bind to TMEM16A (“TMEM16A binding molecules”), particularly human or humanized antibodies and antibody drug conjugates that bind to human TMEM16A and modulate its functions. Epitopes of TMEM16A and molecules that bind these epitopes are also provided herein.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: June 2, 2015
    Assignee: NOVARTIS AG
    Inventors: Larry Alexander Gaither, Christopher John Rothwell
  • Patent number: 9040671
    Abstract: The present disclosure relates to a Co-029 inhibitor for inhibiting the migration of cancer cells which express Co-029. The disclosure relates to a Co-029 inhibitor for the treatment of cancer and/or the prevention of cancer metastasis and pharmaceutical compositions comprising said inhibitor and provides Co-029 antibodies. The disclosure provides a method for predicting the response of a patient afflicted with or susceptible to be afflicted with cancer to a medical treatment with a Co-029 inhibitor, a method for diagnosing a cancer in a patient and a method for predicting the survival in a cancer patient.
    Type: Grant
    Filed: July 22, 2011
    Date of Patent: May 26, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Paris X1 Paris Sud
    Inventors: Eric Rubinstein, Céline Greco, François Le Naour, Claude Boucheix
  • Patent number: 9034328
    Abstract: The present invention relates to an antibody or an antibody fragment thereof which recognizes an extracellular domain of erbB3 and inhibit EGF-like ligand-dependent phosphorylation of erbB3, a DNA encoding the antibody or the antibody fragment thereof, a method of producing the antibody or the antibody fragment thereof, a therapeutic drug including the antibody or the antibody fragment thereof, and therapeutic application using the antibody or the antibody fragment thereof.
    Type: Grant
    Filed: June 20, 2012
    Date of Patent: May 19, 2015
    Assignee: KYOWA HAKKO KIRIN CO., LTD
    Inventor: Nobuaki Takahashi
  • Patent number: 9029513
    Abstract: A cell growth inhibitor that includes, as an antibody component, an artificially produced anti-EGFR antibody having specific binding capacity to EGFR which is characterized in that an epitope therefor is in a cysteine-rich subdomain 2 (C2 domain) and/or in a ligand-binding domain 1 (L1 domain) among four subdomains contained in the extracellular domain of EGFR.
    Type: Grant
    Filed: June 3, 2011
    Date of Patent: May 12, 2015
    Assignees: Toagosei Co. Ltd., Keio University
    Inventors: Nobuyoshi Shimizu, Atsushi Takayanagi, Tetsuhiko Yoshida
  • Patent number: 9023999
    Abstract: The present invention provides a monoclonal antibody which specifically recognizes CD27 containing an O-linked sugar chain to which galactose is not bound and binds to its extracellular region, or a method for using the same. The present invention can provide a monoclonal antibody or an antibody fragment thereof, which specifically recognizes a polypeptide encoded by CD27 gene containing an O-linked sugar chain to which galactose is not bound, and binds to its extracellular region; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which comprises the DNA; a transformant obtainable by transforming the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a diagnostic agent or a therapeutic agent comprising the antibody or the antibody fragment thereof as an active ingredient.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: May 5, 2015
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Katsuhiro Mori, Naoko Hiura, Tsuguo Kubota, Akiko Furuya, Yutaka Kanda, Mitsuo Satoh
  • Patent number: 9017677
    Abstract: A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising an interleukin-6 (IL-6) antagonist, for example an antibody directed against IL-6 receptor, an antibody directed against IL-6, an antibody directed against gp130, and the like.
    Type: Grant
    Filed: January 25, 2006
    Date of Patent: April 28, 2015
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventor: Masahiko Mihara
  • Patent number: 9017957
    Abstract: An object of the present invention is to provide an antibody that can be stably supplied and can react with prostasin under non-denaturation and denaturation conditions, and an antigen peptide for preparation of the antibody. The present invention relates to a peptide consisting of the amino acid sequence shown in SEQ ID NO: 1 or a peptide consisting of an amino acid sequence that has a deletion, a substitution, or an addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1 and having antigenicity of prostasin. Furthermore, the present invention relates to an antibody prepared using the peptide as an antigen.
    Type: Grant
    Filed: May 1, 2007
    Date of Patent: April 28, 2015
    Assignees: Hitachi Chemical Company, Ltd., Kimio Tomita, Kenichiro Kitamura
    Inventors: Hiromi Iijima, Noriya Ohta, Kimio Tomita, Kenichiro Kitamura
  • Patent number: 8987423
    Abstract: Antigen binding proteins, such as antibodies, which bind to human MAGE-A3, polynucleotides encoding such antigen binding proteins, and uses and manufacture thereof.
    Type: Grant
    Filed: July 20, 2011
    Date of Patent: March 24, 2015
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventors: Alain Bergeron, Normand Blais, Remi M. Palmantier, Anthony Pilorget, Yves Fradet
  • Patent number: 8975382
    Abstract: The present invention relates to amino acid sequences and Nanobodies that are directed against Epidermal Growth Factor Receptor 2 (HER2), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: November 27, 2008
    Date of Patent: March 10, 2015
    Assignee: Ablynx N.V.
    Inventors: Hilde Adi Pierrette Revets, Carlo Boutton, Hendricus Renerus Jacobus Mattheus Hoogenboom
  • Patent number: 8961980
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, and hepatocellular cancer.
    Type: Grant
    Filed: December 11, 2012
    Date of Patent: February 24, 2015
    Assignees: Ganymed Pharmaceuticals AG, Johannes Gutenberg-Universitat Mainz
    Inventors: Ugar Sahin, Michael Koslowski, Ozlem Tureci
  • Patent number: 8962806
    Abstract: The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor CCR4. This antibody is derived from Mab 1567 and recognizes the same epitope. Binding of the invented antibody to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.
    Type: Grant
    Filed: December 29, 2008
    Date of Patent: February 24, 2015
    Assignees: Dana-Farber Cancer Institute, Inc., The Bingham and Women's Hospital
    Inventors: Wayne Marasco, Jianhua Sui, Quan Zhu, Thomas Kupper
  • Patent number: 8951972
    Abstract: Methods of treating cancer comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are provided. Dosage packs comprising an FGFR1 ECD and/or an FGFR1 ECD fusion molecule and/or at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are also provided. In some embodiments, a dosage pack comprises instructions for administering FGFR1 ECD and/or FGFR1 ECD fusion molecule with at least one additional therapeutic agent.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: February 10, 2015
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Li Long, Thomas Brennan
  • Patent number: 8945569
    Abstract: Antibodies that specifically bind to an extracellular domain of human Jagged 1 or human Jagged2 and modulate Jagged activity, and methods of using said antibodies to inhibit tumor growth are disclosed. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an anti-Jagged antibody to a patient having a tumor or cancer.
    Type: Grant
    Filed: November 19, 2010
    Date of Patent: February 3, 2015
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Timothy Charles Hoey, Aaron Ken Sato, Alexandra Lazetic, Zhimin Ji
  • Patent number: 8945566
    Abstract: The invention provides a method for increasing the bioactivity (e.g. the biosafety and efficacy) of a therapeutic IgE antibody of the invention in the treatment of a patient. Methods of the invention include: i) administering to the patient a therapeutic IgE antibody in combination with at least one bioactivity-enhancing agent, ii) strategic treatment regimens and protocols for the dosing and administration of a therapeutic IgE antibody of the invention, and iii) the use of a therapeutic IgE antibody having a variable region comprising at least one antigen binding region specific for binding an epitope of an antigen wherein the epitope is not highly repetitive or is non-repetitive.
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: February 3, 2015
    Assignee: Quest PharmaTech, Inc.
    Inventors: Birgit C. Schultes, Christopher F. Nicodemus
  • Patent number: 8945570
    Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: February 3, 2015
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Robert Kendall Morrison, Arthur B. Raitano, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen Jane Meyrick Morrison, Mary Faris, Wangmao Ge, Jean Gudas, Steven B. Kanner
  • Patent number: 8940871
    Abstract: The invention provides novel humanized antibody fragments that specifically bind prostate cell-surface antigen (PSCA), a protein which is overexpressed in variety of cancers, including prostate, bladder, and pancreatic cancer. Methods are provided for the use of the compositions of the invention for the treatment of cancer, diagnosis of cancer, to provide a prognosis of cancer progression, and for cancer imaging.
    Type: Grant
    Filed: March 20, 2007
    Date of Patent: January 27, 2015
    Assignee: The Regents of the University of California
    Inventors: Anna M. Wu, Robert E. Reiter
  • Patent number: 8940298
    Abstract: The present invention provides novel high affinity antibodies and fragments thereof that bind to the cancer antigen PSCA. The antibodies of the present invention may be used for cancer diagnosis, prognosis, treatment, visualization, and the like. The present invention also provides methods for the detection, visualization, and treatment of various cancers expressing PSCA.
    Type: Grant
    Filed: September 4, 2008
    Date of Patent: January 27, 2015
    Assignee: The Regents of the University of California
    Inventors: Anna M. Wu, Robert E. Reiter, Eric J. Lepin, James D. Marks, Yu Zhou
  • Patent number: 8921525
    Abstract: [Problem] Disclosed is an antibody that exhibits excellent cytotoxicity and cell growth inhibition and that is based on an anti-human epithelial cell growth factor receptor (1) (Her1) antibody (528). Further disclosed is a method for producing same, and the like. [Solution] The mutant of an H chain humanized variable region (5H) or an L chain humanized variable region (5L) of the anti-human epithelial cell growth factor receptor (1) (Her1) antibody (528) is the aforementioned antibody characterized by having one to a plurality (for example: 1 to 5, or 1 to 3) of amino acid mutations within CDR2. Further disclosed are antibody molecules containing said region, a nucleic acid molecule coding for these polypeptides, a method for producing said antibody molecules, and the like.
    Type: Grant
    Filed: November 11, 2010
    Date of Patent: December 30, 2014
    Assignee: Tohoku University
    Inventors: Izumi Kumagai, Takeshi Nakanishi, Ryutaro Asano, Mitsuo Umetsu
  • Patent number: 8920803
    Abstract: A method for the treatment of a condition which is characterized by CD 123-expressing cells in a patient comprises administering to the patient (i) an antibody or antibody fragment which binds selectively to IL-3R?(CD 123), and (ii) an immunostimulating complex which comprises saponin, a sterol and a phospholipid.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: December 30, 2014
    Assignee: CSL Limited
    Inventors: Debra Pauline Drane, Eugene Maraskovsky, Jefferey Stephen Boyle
  • Publication number: 20140363873
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: May 8, 2014
    Publication date: December 11, 2014
    Applicant: Genentech, Inc.
    Inventors: Mark Dennis, Bonnee Rubinfeld, Paul Polakis
  • Patent number: 8901278
    Abstract: The present invention relates to pharmaceutical compositions for the treatment of an epithelial tumor in a human, said pharmaceutical composition comprising an IgG1 antibody specifically binding to human CEA, wherein the variable region of said IgG1 antibody comprises at least (i) a CDR-H1 having the amino acid sequence “SYWMH” (SEQ ID NO: 29) and a CDR-H2 having the amino acid sequence “FIRNKANGGTTEYAASVKG” (SEQ ID NO: 28) and a CDR-H3 having the amino acid sequence “DRGLRFYFDY” (SEQ ID NO: 27) or (ii) a CDR-H1 having the amino acid sequence “TYAMH” (SEQ ID NO: 31) and a CDR-H2 having the amino acid sequence “LISNDGSNKYYADSVKG” (SEQ ID NO: 30) and a CDR-H3 having the amino acid sequence “DRGLRFYFDY” (SEQ ID NO: 27). Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the IgG1 antibody molecules bearing specificities for the human CEA antigen are disclosed.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: December 2, 2014
    Assignee: Amgen Research (Munich) GmbH
    Inventors: Doris Rau, Susanne Mangold, Peter Kufer, Tobias Raum
  • Patent number: 8895703
    Abstract: The CA125 gene has been cloned and multiple repeat sequences as well as the carboxy terminus have been identified. The CA125 molecule comprises three major domains: an extracellular amino terminal domain (Domain 1); a large multiple repeat domain (Domain 2); and a carboxy terminal domain (Domain 3) which includes a transmembrane anchor with a short cytoplasmic domain. An amino terminal extension is present. The molecular structure is dominated by a repeat domain comprising 156 amino acid repeat units. More than 60 repeat units have been identified, sequenced, and contiguously placed in the CA125 domain structure. The repeat units encompass an interactive disulfide bridged C-enclosure and the site of OC125 and M11 binding. The repeat sequences demonstrated 70-85% homology to each other. Expression of the repeats was demonstrated in E. coli. The CA125 molecule is anchored at its carboxy terminal through a transmembrane domain and a short cytoplasmic tail.
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: November 25, 2014
    Assignee: The Board of Trustees for the University of Arkansas
    Inventors: Timothy O'Brien, John Beard, Lowell Underwood
  • Patent number: 8883980
    Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: November 11, 2014
    Assignee: Roche Glycart AG
    Inventors: Pablo Umaña, Peter Brünker, Claudia Ferrera Koller, Tobias Suter, Ursula Püntener, Ekkehard Mössner
  • Patent number: 8877199
    Abstract: The invention relates to antibodies that are reactive to the cell surface of CD19+ B cells, including B-cell chronic lymphocytic leukemia (B-CLL) cells, and compositions and methods for using such antibodies, including in the diagnosis and treatment of disorders associated with CD19+ B cells, such as B-CLL.
    Type: Grant
    Filed: May 12, 2010
    Date of Patent: November 4, 2014
    Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human Services
    Inventors: Christoph Rader, Sivasubramanian Baskar, Michael R. Bishop, Ivan Samija, Jessica M. Suschak
  • Patent number: 8871204
    Abstract: The present invention relates to modified Fc-containing molecules including modified antibodies characterized by increased resistance to host and pathogen-derived proteases, ability to interact with Fc?R receptors except with Fc?RI, and lack of induction of IL-10 secretion by macrophages, and methods of using and making them.
    Type: Grant
    Filed: July 23, 2012
    Date of Patent: October 28, 2014
    Assignee: Janssen Biotech, Inc.
    Inventors: Randall Brezski, Robert Jordan, William Strohl
  • Patent number: 8871908
    Abstract: The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.
    Type: Grant
    Filed: November 7, 2012
    Date of Patent: October 28, 2014
    Assignee: Rinat Neuroscience Corp.
    Inventors: Shu-Hui Liu, Wei-Hsien Ho, Pavel Strop, Magdalena Grazyna Dorywalska, Arvind Rajpal, David Louis Shelton, Thomas-Toan Tran
  • Patent number: 8865873
    Abstract: This invention provides a method that allows selection of antibodies against cells (e.g., tumor cells) in situ using laser capture microdissection. By restricting antibody selection to binders of internalizing epitopes, a panel of phage antibodies was generated that targets clinically represented prostate cancer antigens.
    Type: Grant
    Filed: March 15, 2010
    Date of Patent: October 21, 2014
    Assignee: The Regents of the University of California
    Inventors: Bin Liu, James D. Marks
  • Patent number: 8858942
    Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to ErbB2, preferably human ErbB2. In another embodiment, the antibodies or antigen-binding portions thereof inhibit ErbB2. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins or portions thereof derived from human anti-ErbB2 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-ErbB2 antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
    Type: Grant
    Filed: December 11, 2012
    Date of Patent: October 14, 2014
    Assignee: MedImmune Limited
    Inventors: Susan Ann Cartlidge, Jianying Dong, Mark Hickinson, Ian Foltz, Jaspal Singh Kang
  • Patent number: 8853364
    Abstract: PSCA and its encoded protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.
    Type: Grant
    Filed: September 17, 2009
    Date of Patent: October 7, 2014
    Assignee: Agensys, Inc.
    Inventors: Wangmao Ge, Pia M. Challita-Eid, Arthur B. Raitano, Aya Jakobovits
  • Patent number: 8846872
    Abstract: The disclosure relates to antibodies to the preferentially expressed antigen in melanoma (PRAME), and the synovial sarcoma X breakpoint 2 (SSX-2) antigens, methods of use, and diagnostic kits thereof. In exemplary embodiments, the disclosure relates to monoclonal antibodies to specific epitopes of the PRAME and SSX-2 antigens and methods of using such antibodies.
    Type: Grant
    Filed: November 18, 2010
    Date of Patent: September 30, 2014
    Assignee: MannKind Corporation
    Inventors: Nathalie Kertesz, Sutao Zhu, Chih-Sheng Chiang
  • Patent number: 8841421
    Abstract: A method of identifying a compound for use in therapy which modulates the interaction of S1OO A9 with a ligand comprising:—determining whether a candidate compound is capable of modulating the interaction of S1OO A9 with RAGE or the interaction of S1OO A9 with a TLR (Toll like receptor), or—determining whether a candidate compound is capable of binding to S100A9 in a manner which disrupts binding of S1OO A9 with RAGE or the binding of S100A9 with a TLR, to thereby identify whether the compound may be used in therapy.
    Type: Grant
    Filed: April 24, 2008
    Date of Patent: September 23, 2014
    Assignee: Active Biotech, AB
    Inventors: Per Bjork, Frederik Ivars, Tomas Leanderson
  • Patent number: 8828717
    Abstract: The present disclosure provides humanized COL-1 monoclonal antibodies that retain CEA binding affinity, compared to a parent antibody. Also disclosed herein are humanized COL-1 monoclonal antibodies that have reduced immunogenicity, compared to a parent antibody. The disclosed humanized COL-1 antibodies include substitution of framework residues with residues from the corresponding positions of a homologous human sequence. In several embodiments, methods are disclosed for the use of a humanized COL-1 antibody in the detection or treatment of a CEA-expressing tumor or cell in a subject. Also disclosed is a kit including the humanized COL-1 antibodies described herein.
    Type: Grant
    Filed: November 15, 2010
    Date of Patent: September 9, 2014
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Jeffrey Schlom, Eduardo A. Padlan, Rafia Mehdi Kashmiri
  • Patent number: 8822648
    Abstract: An anti-CEA scFv having an uncleaved Pel B leader sequence is surprisingly stable and is highly specific for CEA and CEACAM1.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: September 2, 2014
    Assignees: Instituto Superiore di Sanita, Diatheva s.r.l.
    Inventors: Maurizio Cianfriglia, Michela Flego, Alessandro Ascione, Valentina Fiori, Sabrina Domicini, Alessandra Mallano, Diego Moricoli, Silvia Zamboni
  • Publication number: 20140234327
    Abstract: The invention discloses a monoclonal antibody against human non-small cell lung carcinoma and a use of the monoclonal antibody. The monoclonal antibody is secreted by a hybridoma cell strain which is deposited as CCTCC Access Number No.: C201172. It has high yield and high titer, and has specific reactivity against lung adenocarcinoma and squamous carcinoma cell lines. Therefore, the monoclonal antibody may be applied in preparing drugs for treating human non-small cell lung carcinoma.
    Type: Application
    Filed: January 12, 2012
    Publication date: August 21, 2014
    Inventors: Shiyan Pan, Peijun Huang, Fang Wang
  • Patent number: 8808667
    Abstract: The present invention relates to the use of a milled homogenate and/or a suspension and/or a cell lysate, stemming from a tumor resistant to at least one anti-tumoral compound in order to immunize and generate in vitro an antibody, or one of its functional fragments, directed against a tumoral antigen specifically expressed at the surface of said resistant tumor and being possibly involved in the resistance of said resistant tumor. More particularly, the present invention is directed to such antibodies obtained by applying the method, such as the antibodies 1A6, 1A9, 2E11, 3C11 and 3G7, as well as to their use for treating cancer.
    Type: Grant
    Filed: July 9, 2012
    Date of Patent: August 19, 2014
    Assignee: Pierre Fabre Medicament
    Inventors: Liliane Goetsch, Alexandra Jouhanneaud
  • Patent number: 8802103
    Abstract: Monoclonal antibodies that specifically bind to an extracellular domain of human Jagged 1 and inhibit growth of a tumor comprising cancer stem cells are described. Also described is a method of treating cancer that comprises administering a therapeutically effective amount of a monoclonal anti-Jagged 1 antibody.
    Type: Grant
    Filed: May 15, 2008
    Date of Patent: August 12, 2014
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin Gurney, Timothy Hoey, Sanjeev Satyal, Maureen Fitch Bruhns
  • Patent number: 8802826
    Abstract: Antibodies and antigen binding fragments that specifically bind to clusterin are described. In some embodiments, the antibodies block the biological activity of clusterin and are useful in composition in certain cancers, more particularly in cancers, such as endometrial carcinoma, breast carcinoma, hepatocellular carcinoma, prostate carcinoma, a renal cell carcinoma, ovarian carcinoma, pancreatic carcinoma, and colorectal carcinoma. The invention also relates to cells expressing the humanized or hybrid antibodies. Additionally, methods of detecting and treating cancer using the antibodies and fragments are also disclosed.
    Type: Grant
    Filed: November 24, 2010
    Date of Patent: August 12, 2014
    Assignees: Alethia Biotherapeutics Inc., National Research Council of Canada
    Inventors: Gilles Bernard Tremblay, Mario Filion, Traian Sulea
  • Patent number: 8790649
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: July 29, 2014
    Assignee: ImmunoGen, Inc.
    Inventors: Julianto Setiady, Peter U. Park, Lingyun Rui, Thomas Chittenden, Gillian Payne
  • Patent number: 8791244
    Abstract: The present invention provides antibodies that bind to ErbB3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human ErbB3. In certain embodiments, the antibodies of the present invention block the interaction of ErbB3 with an ErbB3 ligand such as neuregulin 1. The antibodies of the invention are useful for the treatment of various cancers.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: July 29, 2014
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Christopher Daly, Douglas MacDonald, Xunbao Duan
  • Patent number: 8779108
    Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.
    Type: Grant
    Filed: November 24, 2010
    Date of Patent: July 15, 2014
    Assignee: MedImmune, Limited
    Inventors: Christophe Queva, Michelle Morrow, Scott Hammond, Marat Alimzhanov, John Babcook, Ian Nevin Foltz, Jaspal Singh Kang, Laura Sekirov, Melanie Boyle, Matthieu Chodorge, Ross A. Stewart, Kathleen Ann Mulgrew
  • Patent number: 8779092
    Abstract: The present invention concerns peptide sequences that specifically recognize cells of human hepatic metastases. The invention comprises also the use of nucleic acids coding for such peptides, as well as conjugates and formulations of such peptides for diagnostic and therapeutic purposes.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: July 15, 2014
    Assignee: Universita Degli Studi di Torino
    Inventors: Federico Bussolino, Serena Marchio